An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. Davì S, Consolaro A, Guseinova D, Pistorio A, Ruperto N, Martini A, Cron RQ, Ravelli A; MAS Study Group. J Rheumatol. 2011 Apr;38(4):764-8. PMID:  21285158.

Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Ravelli A, Grom AA, Behrens EM, Cron RQ. Genes Immun. 2012 Jun;13(4):289-98. PMID:  22418018.

Intensive care requirement, rather than degree of serum ferritin elevation, predicts mortality in macrophage activation syndrome. Mannion ML, Cron RQ. Pediatr Crit Care Med. 2012 Sep;13(5):616; author reply 616-7. PMID:  22955471.

Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Rheumatology (Oxford). 2010 Aug 7. [Epub ahead of print] PMID: 20693540.  .pdf

Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). Behrens EM, Beukelman T, Gallo L, Spangler J, Rosenkranz M, Arkachaisri T, Ayala R, Groh B, Finkel TH, Cron RQ. J Rheumatol. 2008 Feb;35(2):343-8. Epub 2007 Dec 15.PMID: 18085728.  .pdf

Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. Behrens EM, Beukelman T, Paessler M, Cron RQ. J Rheumatol. 2007 May;34(5):1133-8. Epub 2007 Mar 1.PMID: 17343315.  .pdf

Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. Behrens EM, Kreiger PA, Cherian S, Cron RQ. J Rheumatol. 2006 Oct;33(10):2081-4.PMID: 17014024.  .pdf